Download Files:
Irpagratinib
$840 – $3,400
Products Details
Product Description
– Irpagratinib (ABSK011) is an orally active inhibitor of fibroblast growth factor receptor (FGFR) tyrosine kinase, targeting to FGFR4 (IC50<10 nM). Irpagratinib inhibits the auto-phosphorylation of FGFR4 and blocks signal transduction from FGFR4 to downstream pathway activation. Irpagratinib exhibits high exposure in PK study in mouse, rat and dog, and also shows antineoplastic/anti-tumor activity in subcutaneous xenograft tumor models[1].
Web ID
– HY-156618
Shipping
– Room temperature
Molecular Formula
– C28H32F2N6O5
References
– [1]Chen Z. Abstract LB-272: Discovery and characterization of a novel FGFR4 Inhibitor for the treatment of hepatocellular carcinoma[J]. Cancer Research, 2018, 78(13_Supplement): LB-272-LB-272.
CAS Number
– 2230974-62-4
Molecular Weight
– 570.59
SMILES
– FC(C(OC)=CC(OC)=C1F)=C1C2=CC(C=N3)=C(C(N4CC(C)(C4)OC)=N2)N=C3N[C@H]5[C@H](CCOC5)NC(C=C)=O
Clinical Information
– No Development Reported
Research Area
– cancer
Solubility
– 10 mM in DMSO
Target
– FGFR
Pathway
– Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
